Get the Stockscreener App
150.59
1.09%
-1.66
After Hours:
152.51
1.92
+1.27%
Neurocrine Biosciences Inc stock is traded at $150.59, with a volume of 1.21M.
It is down -1.09% in the last 24 hours and up +16.84% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$152.25
Open:
$152
24h Volume:
1.21M
Relative Volume:
1.01
Market Cap:
$15.14B
Revenue:
$2.86B
Net Income/Loss:
$478.60M
P/E Ratio:
32.26
EPS:
4.6676
Net Cash Flow:
$748.70M
1W Performance:
+12.32%
1M Performance:
+16.84%
6M Performance:
+2.24%
1Y Performance:
+30.14%
1-Day Range:
$150.32
$154.44
1-Week Range:
$132.76
$154.74
52-Week Range:
$116.00
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
150.59 | 15.31B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.36 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.84 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.98 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.67 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
569.88 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations - Investing.com
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations By Investing.com - Investing.com Canada
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus - Yahoo Finance Singapore
MSN Money - MSN
Neurocrine Biosciences Stock On Fire: Up 19% With 10-Day Winning Streak - Trefis
Neurocrine Biosciences Stock 10-Day Winning Spree: Stock Climbs 19% - Trefis
Neurocrine Biosciences stock (US62886E1082): Analysts lift price targets after strong Q1 2026 result - AD HOC NEWS
Neurocrine Is Maintained at Overweight by JP Morgan - Moomoo
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus - TradingView
Neurocrine Friedreich ataxia asset granted FDA orphan status - MSN
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Neurocrine Biosciences, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Earnings Beat: Neurocrine Biosciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Neurocrine Biosciences Stock Rockets 17% With 9-Day Winning Streak - Trefis
Neurocrine Biosciences Stock 9-Day Winning Spree: Stock Climbs 17% - Trefis
Neurocrine Is Maintained at Buy by Truist Securities - Moomoo
Neurocrine (NBIX) Q1 2026 Earnings Transcript - AOL.com
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Neurocrine Biosciences Q1 2026 earnings preview - MSN
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine Biosciences Stock 8-Day Winning Spree: Stock Climbs 15% - Trefis
Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability - simplywall.st
Research Alert: CFRA Keeps Hold Rating On Shares Of Neurocrine Biosciences Inc. - 富途牛牛
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside - Seeking Alpha
Oppenheimer Adjusts Price Target on Neurocrine Biosciences to $230 From $220, Maintains Outperform Rating - Moomoo
Truist raises Neurocrine Bio stock price target on strong sales By Investing.com - Investing.com Canada
Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains? - Yahoo Finance
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia - BioSpace
Oppenheimer raises Neurocrine Bio stock price target on strong results By Investing.com - Investing.com India
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
New CRENESSITY guidance on cutting high steroid doses in CAH - Stock Titan
Neurocrine publishes expert guidelines for glucocorticoid reduction with CRENESSITY - StreetInsider
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia – Company AnnouncementFT.com - Financial Times
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript - Insider Monkey
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $200 - Moomoo
Neurocrine Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Neurocrine Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Neurocrine Biosciences surges 8% as INGREZZA sales drive better-than-expected Q1 results - Investing.com Nigeria
Neurocrine Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NBIX) 2026-05-05 - Seeking Alpha
Neurocrine Q1 2026 slides: revenue surges 44% on dual-product strength - Investing.com
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat By Investing.com - Investing.com Australia
Neurocrine Biosciences : Presentation (NBIX Q1 2026 Earnings Presentation Final 0556) - marketscreener.com
Neurocrine Biosciences (NBIX) Valuation Check After New Long Term CRENESSITY Phase 3 Data - simplywall.st
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat - Investing.com
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
6.66%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):